Mirati Ther (MRTX)

63.35
+3.74(+6.27%)
After Hours
63.30
-0.05(-0.08%)
- Real-time Data
  • Volume:
    821,340
  • Day's Range:
    60.23 - 63.77
  • 52 wk Range:
    51.16 - 195.99

MRTX Overview

Prev. Close
59.61
Day's Range
60.23-63.77
Revenue
72.8M
Open
62.11
52 wk Range
51.16-195.99
EPS
-11.9
Volume
821,340
Market Cap
3.52B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
722,112
P/E Ratio
-
Beta
1.58
1-Year Change
-58.75%
Shares Outstanding
55,526,877
Next Earnings Date
Aug 04, 2022
What is your sentiment on Mirati Ther?
or
Market is currently closed. Voting is open during market hours.

Mirati Ther News

Mirati Ther Analysis

Mirati Ther Company Profile

Mirati Ther Company Profile

Employees
0

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell